These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17311616)

  • 41. Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease.
    Rossi F; Bellini G; Alisi A; Alterio A; Maione S; Perrone L; Locatelli F; Miraglia del Giudice E; Nobili V
    PLoS One; 2012; 7(8):e42259. PubMed ID: 22927922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis.
    Floreani A; Lazzari R; Macchi V; Porzionato A; Variola A; Colavito D; Leon A; Guido M; Baldo V; De Caro R; Bergasa NV
    J Gastroenterol; 2010; 45(1):68-76. PubMed ID: 19730968
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.
    Flores-Contreras L; Sandoval-Rodríguez AS; Mena-Enriquez MG; Lucano-Landeros S; Arellano-Olivera I; Alvarez-Álvarez A; Sanchez-Parada MG; Armendáriz-Borunda J
    BMC Gastroenterol; 2014 Jul; 14():131. PubMed ID: 25064094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study.
    Ashton JC; Friberg D; Darlington CL; Smith PF
    Neurosci Lett; 2006 Mar; 396(2):113-6. PubMed ID: 16356641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Expression of cannabinoid receptor 2 in squamous cell carcinoma].
    Zhao ZG; Li YY; Yang J; Li HJ; Zhao H
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):593-5. PubMed ID: 20335147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Iron and fibrosis in nonalcoholic fatty liver disease.
    MacDonald GA; Ward PJ; George DK; Powell LW
    Hepatology; 2000 Feb; 31(2):549-50. PubMed ID: 10691383
    [No Abstract]   [Full Text] [Related]  

  • 47. Ultrastructure of hepatocyte mitochondria in nonalcoholic steatohepatitis in pediatric patients: usefulness of electron microscopy in the diagnosis of the disease.
    Sobaniec-Lotowska ME; Lebensztejn DM
    Am J Gastroenterol; 2003 Jul; 98(7):1664-5. PubMed ID: 12873608
    [No Abstract]   [Full Text] [Related]  

  • 48. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.
    Richart C; Auguet T; Terra X
    N Engl J Med; 2010 Jul; 363(2):193-4; author reply 195. PubMed ID: 20647217
    [No Abstract]   [Full Text] [Related]  

  • 49. Molecular pathogenesis of nonalcoholic steatohepatitis: today and tomorrow.
    Alisi A; Nobili V
    Am J Pathol; 2007 Aug; 171(2):712-3; author reply 713. PubMed ID: 17569778
    [No Abstract]   [Full Text] [Related]  

  • 50. Osteopontin: a missing link between hedgehog signaling and fibrosis in nonalcoholic steatohepatitis.
    Machado MV; Cortez-Pinto H
    Hepatology; 2011 Feb; 53(2):382-4. PubMed ID: 21274859
    [No Abstract]   [Full Text] [Related]  

  • 51. [Comparison of two nonalcoholic hepatocellular steatosis models].
    Wu HR; Chen SH; Lu Y; Li YM
    Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):297-9. PubMed ID: 20460052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.
    Lake AD; Novak P; Fisher CD; Jackson JP; Hardwick RN; Billheimer DD; Klimecki WT; Cherrington NJ
    Drug Metab Dispos; 2011 Oct; 39(10):1954-60. PubMed ID: 21737566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [An experimental study on the expression and pathogenic effects of cyclooxygenase-2 in nonalcoholic fatty liver disease].
    Cao MB; Dong L; Lu XL; Luo JY
    Zhonghua Gan Zang Bing Za Zhi; 2008 Apr; 16(4):315-6. PubMed ID: 18423164
    [No Abstract]   [Full Text] [Related]  

  • 54. [The significance of resistin expression in livers of patients with nonalcoholic fatty liver disease].
    Zhao CY; Kong LB; Wang YD
    Zhonghua Gan Zang Bing Za Zhi; 2008 Aug; 16(8):630-1. PubMed ID: 18752757
    [No Abstract]   [Full Text] [Related]  

  • 55. Nonalcoholic steatohepatitis: lots of hype, how much substance?
    Acharya SK; Batra Y
    Trop Gastroenterol; 2002; 23(3):111-2. PubMed ID: 12693149
    [No Abstract]   [Full Text] [Related]  

  • 56. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis.
    Lonardo A; Carani C; Carulli N; Loria P
    J Hepatol; 2006 Jun; 44(6):1196-207. PubMed ID: 16618516
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunohistochemical analysis in steatohepatitis: does it have a role in diagnosis and management?
    Snover D
    Am J Clin Pathol; 2005 Apr; 123(4):491-3. PubMed ID: 15743741
    [No Abstract]   [Full Text] [Related]  

  • 58. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy.
    Itoh S; Igarashi M; Tsukada Y; Ichinoe A
    Acta Hepatogastroenterol (Stuttg); 1977 Dec; 24(6):415-8. PubMed ID: 74931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Laparoscopy findings of the yellow spot, a focal fatty liver infiltration].
    Koch H; Henning H; Friedrich K; Lüders CJ
    Z Gastroenterol; 1984 May; 22(5):250-4. PubMed ID: 6234714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Determination of cellular and humoral parameters of fatty liver].
    Götze D; Neuendorf R; Kleine FD; Ittenson A; Mansfeld HW; Schön E; Ansorge S
    Allerg Immunol (Leipz); 1989; 35(1):65-8. PubMed ID: 2718889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.